Personalizing Care in MG

The conversation shifts to the effectiveness of targeted therapies in personalizing patient care for patients with myasthenia gravis (MG). Participants discuss the challenges of incorporating these therapies alongside existing treatments and effectively communicating options to patients. They emphasize the importance of breaking down complex information into manageable parts for both patients and providers.

Clinical trial participation is highlighted as crucial for advancing therapies, with recognition of patients' contributions and the benefits of improved access to care. However, there's concern about disparities in trial recruitment, particularly in North America, and the need for better outreach and adaptation of trial methodologies to ensure inclusivity.

The looming concern is whether current practices can sustain the demand for new therapies, given the growing pipeline and conceptualized treatments. This prompts a call for reflection on trial recruitment practices and potential regulatory hurdles to ensure continued progress in patient care.